AInvest Newsletter
Daily stocks & crypto headlines, free to your inbox
Top Analysts Pick 3 Stocks with 300% Upside Potential
ByAinvest
Friday, Aug 15, 2025 7:52 am ET1min read
Three stocks to buy now, according to top analysts, are Larimar Therapeutics (LRMR), Chipotle (CMG), and Spire Global (SPIR). All three stocks have received new Buy ratings and have significant upside potential. Larimar Therapeutics has a 304.93% upside, Chipotle has a 35.77% upside, and Spire Global has a 51.75% upside. TipRanks' Analyst Top Stocks tool can help investors find more stocks like these.
In the dynamic landscape of the stock market, analysts' ratings can serve as valuable indicators for investors. According to recent analyses, Larimar Therapeutics (LRMR), Chipotle (CMG), and Spire Global (SPIR) have received new Buy ratings, each with significant upside potential. Here's a breakdown of these stocks:Larimar Therapeutics (LRMR)
Larimar Therapeutics has maintained a strong Buy rating with a price target of $26.00 from Guggenheim [1]. The stock is currently trading at $4.24, suggesting a potential 304.93% upside. Analysts have a strong consensus, with price targets ranging from $10 to $40. Larimar is expected to present initial open-label extension (OLE) data in September 2025, which could provide significant catalysts for the stock. The company has also extended its cash runway into the fourth quarter of 2026 following a recent capital raise.
Chipotle (CMG)
Chipotle has received a new Buy rating with a price target of $475.00 from TipRanks, suggesting a 35.77% upside. The stock is currently trading at $350.00. Chipotle's strong financial performance and growing market share have positioned it as a favorite among analysts.
Spire Global (SPIR)
Spire Global has been given a new Buy rating with a price target of $37.00 from TipRanks, indicating a 51.75% upside. The stock is currently trading at $24.00. Spire Global's focus on environmental, social, and governance (ESG) factors, along with its innovative technology, has attracted analyst interest.
These stocks offer compelling upside potential based on analyst ratings. Investors should consider these opportunities carefully, taking into account their own risk tolerance and investment goals. For more insights, consider using tools like TipRanks' Analyst Top Stocks tool.
References:
[1] https://za.investing.com/news/analyst-ratings/larimar-therapeutics-stock-maintains-buy-rating-at-guggenheim-ahead-of-key-data-93CH-3841174
Ainvest News articles are AI-generated using advanced large language model (LLM) technology designed to analyze and synthesize publicly available data and news. While AI tools assist in producing initial drafts and insights, all AI generated content published on Ainvest is subject to comprehensive human editorial review before publication. A designated human editor reviews, verifies, and approves each article for factual accuracy, coherence, and compliance with AInvest Fintech Inc’s editorial and disclosure standards.
Despite these review procedures, the information provided may still contain inaccuracies, incomplete data, or time sensitive references due to the inherent limitations of AI generated analysis and evolving changes. The material is provided strictly for informational and educational purposes and does not constitute personalized investment, legal, or financial advice. Readers should independently verify all facts, figures, and statements before making any decision based on this content.
AInvest Fintech Inc. its affiliates, and partners accept no liability or responsibility for any direct or consequential losses arising from reliance on this content. All articles and analyses are subject to revision, update, or removal without prior notice to maintain accuracy and integrity in our publications.
Comments
No comments yet